Monitoring of Antiresorptive Therapy

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 649-669

  Meier, Christian ^a   Nguyen, Tuan V ^b   Seibel, Markus J ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 43949127209     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50040-6     Document Type: Chapter

References (137)

1. Fleming T.R., DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann. Intern. Med. 1996, 125:605-613.
2. Civitelli R., Gonnelli S., Zacchei F., Bigazzi S., Vattimo A., Avioli L.V., Gennari C. Bone turnover in postmenopausal osteoporosis Effect of calcitonin treatment. J. Clin. Invest. 1988, 82:1268-1274.
3. Overgaard K., Hansen M.A., Nielsen V.A., Riis B.J., Christiansen C. Discontinuous calcitonin treatment of established osteoporosiss-effects of withdrawal of treatment. Am. J. Med. 1990, 89:1-6.
4. Nielsen N.M., von der Recke P., Hansen M.A., Overgaard K., Christiansen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif. Tissue Int. 1994, 55:8-11.
5. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B. Early changes in biochemical markers of bone tumover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J. Bone Miner. Res. 1998, 13:1431-1438.
6. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Montagnani A., Monaco R., Gennari C. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif. Tissue Int. 1999, 65:359-364.
7. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone tumover in late postmenopausal women is a major determinant of osteoporosis. J. Bone. Miner. Res. 1996, 11:337-349.
8. Rosen C.J., Chesnut C.H., Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 1997, 82:1904-1910.
9. Chesnut C.H., Bell N.H., Clark G.S., Drinkwater B.L., English S.C., Johnson C.C., Notelovitz M., Rosen C., Cain D.F., Flessland K.A., Mallinak N.J. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 1997, 102:29-37.
10. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Monaco R., Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J. Bone Miner. Res. 1997, 12:624-631.
11. Hesley R.P., Shepard K.A., Jenkins D.K., Riggs B.L. Monitoring estrogen replacement therapy and identifiying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos. Int. 1998, 8:159-164.
12. Stevenson J.C., Hillard T.C., Lees B., Whitcroft S.I., Ellerington M.C., Whitehead M.I. Postmenopausal bone loss: does HRT always work?. Int. J. Fertil. Menopausal. Stud. 1993, 38(Suppl 2):88-91.
13. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., Black D.M. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 2002, 112:281-289.
14. Seibel M.J., Naganathan V., Barton I., Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J. Bone Miner. Res. 2004, 19:323-329.
15. Epstein S., Poser J., McClintock R., Johnston C.C., Bryce G., Hui S. Differences in serum bone GLA protein with age and sex. Lancet. 1984, 1:307-310.
16. Beardsworth L.J., Eyre D.R., Dickson I.R. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen tumover. J. Bone Miner. Res. 1990, 5:671-676.
17. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 1993, 77:1046-1053.
18. Seibel M.J., Woitge H., Scheidt-Nave C., Leidig-Bruckner G., Duncan A., Nicol P., Ziegler R., Robins S.P. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J. Bone Miner. Res. 1994, 9:1433-1440.
19. Hassager C., Risteli J., Risteli L., Christiansen C. Effect of the menopause and hormone replacement therapy on the carboxyterminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporos. Int. 1994, 4:349-352.
20. Johansen J.S., Riis B.J., Delmas P.D., Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur. J. Clin. Invest. 1988, 18:191-195.
21. Stepan J.J., Pospichal J., Schreiber V., Kanka J., Mensik J., Presl J., Pacovsky V. The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone. Calcif. Tissue Int. 1989, 45:273-280.
22. Uebelhart D., Schlemmer A., Johansen J.S., Gineyts E., Christiansen C., Delmas P.D. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 1991, 72:367-373.
23. Hasling C., Eriksen E.F., Melkko J., Risteli L., Charles P., Mosekilde L., Risteli J. Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. J. Bone Miner. Res. 1991, 6:1295-1300.
24. Reginster J.Y., Christiansen C., Dequinze B., Deroisy R., Gaspard U., Taquet A.N., Franchimont P. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif. Tissue Int. 1993, 53:13-16.
25. Prestwood K.M., Pilbeam C.C., Burleson J.A., Woodiel F.N., Delmas P.D., Deftos L.J., Raisz L.G. The short-term effects of conjugated estrogen on bone turnover in older women. J. Clin. Endocrinol. Metab. 1994, 79:366-371.
26. Cicinelli E., Galantino P., Pepe V., Popolizio A., Savino F., Balzano G., Epifani S., Cantatore F.P. Bone metabolism changes after transdermal estradiol dose reduction during estrogen replacement therapy: a 1-year prospective study. Maturitas. 1994, 19:133-139.
27. Riis B.J., Overgaard K., Christiansen C. Biochemical markers of bone tumover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos. Int. 1995, 5:276-280.
28. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and oste oporosis risk assessment. J. Clin. Endocrinol. Metab. 1995, 80:864-868.
29. Raisz L.G., Wiita B., Artis A., Bowen A., Schwartz S., Trahiotis M., Shoukri K., Smith J. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J. Clin. Endocrinol. Metab. 1996, 81:37-43.
30. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J. Bone Miner. Res. 1998, 13:1124-1133.
31. Cooper C., Stakkestad J.A., Radowicki S., Hardy P., Pilate C., Dain M.P., Delmas P.D. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos. Int. 1999, 9:358-366.
32. Prestwood K.M., Thompson D.L., Kenny A.M., Seibel M.J., Pilbeam C.C., Raisz L.G. Low dose estrogen and calcium have an additive effect on bone resorption in older women. J. Clin. Endocrinol. Metab. 1999, 84:179-183.
33. Recker R.R., Davies K.M., Dowd R.M., Heaney R.P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann. Intern. Med. 1999, 130:897-904.
34. Marcus R., Holloway L., Wells B., Greendale G., James M.K., Wasilauskas C., Kelaghan J. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J. Bone. Miner. Res. 1999, 14:1583-1595.
35. Garnero P., Tsouderos Y., Marton I., Pelissier C., Varin C., Delmas P.D. Effects of intranasal 17beta-estradiol on bone tumover and serum insulin-like growth factor 1 in postmenopausal women. J. Clin. Endocrinol. Metab. 1999, 84:2390-2397.
36. Prestwood K.M., Kenny A.M., Unson C., Kulldorff M. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2000, 85:4462-4469.
37. Delmas P.D., Hardy P., Garnero P., Dain M. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000, 26:553-560.
38. Lindsay R., Gallagher J.C., Kleerekoper M., Pickar J.H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002, 287:2668-2676.
39. Prestwood K.M., Kenny A.M., Kleppinger A., Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003, 290:1042-1048.
40. Valimaki M.J., Laitinen K.A., Tahtela R.K., Hirvonen E.J., Risteli J.P. The effects of transdermal estrogen therapy on bone mass and tumover in early postmenopausal smokers: a prospective, controlled study. Am. J. Obstet. Gynecol. 2003, 189:1213-1220.
41. Nielsen T.F., Ravn P., Bagger Y.Z., Warming L., Christiansen C. Pulsed estrogen therapy in prevention of postmenopausal osteoprosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporos. Int. 2004, 15:168-174.
42. Gallagher J.C., Rapuri P.B., Haynatzki G., Detter J.R. Effect of disecontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J. Clin. Endocrinol. Metab. 2002, 87:4914-4923.
43. Delmas P.D., Pornel B., Felsenberg D., Garnero P., Hardy P., Pilate C., Dain M.P. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group. Bone 1999, 24:517-523.
44. Delmas P.D. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos. Int. 2000, 11(Suppl 6):S66-S76.
45. Anderson J.J., Anthony M.S., Cline J.M., Washburn S.A., Gamer S.C. Health potential of soy isoflavones for menopausal women. Public Health Nutr 1999, 2:489-504.
46. Morabito N., Crisafulli A., Vergara C., Gaudio A., Lasco A., Frisina N., D'Anna R., Corrado F., Pizzoleo M.A., Cincotta M., Altavilla D., Ientile R., Squadrito F. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J. Bone Miner. Res. 2002, 17:1904-1912.
47. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337:1641-1647.
48. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
49. Morii H., Ohashi Y., Taketani Y., Fukumaga M., Nakamura T., Itabashi A., Sarkar S., Harper K. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos. Int. 2003, 14:793-800.
50. Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D., Collette J. Reduction in PINP, a marker of bone metabolism with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004, 34:344-351.
51. Hansdottir H., Franzson L., Prestwood K., Sigurdsson G. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J. Am. Geriatr. Soc. 2004, 52:779-783.
52. Prestwood K.M., Gunness M., Muchmore D.B., Lu Y., Wong M., Raisz L.G. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. 2000, 85:2197-2202.
53. Reid I.R., Eastell R., Fogelman I., Adachi J.D., Rosen A., Netelenbos C., Watts N.B., Seeman E., Ciaccia A.V., Draper M.W. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. 2004, 164:871-879.
54. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 1994, 79:1693-1700.
55. Bone H.G., Downs R.W., Tucci J.R., Harris S.T., Weinstein R.S., Licata A.A., McClung M.R., Kimmel D.B., Gertz B.J., Hale E., Polvino W.J. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J. Clin. Endocrinol. Metab. 1997, 82:265-274.
56. Stepan J.J., Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin. Chim. Acta. 1999, 288:121-135.
57. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., Yates A.J., Bjarnason N.H., Christiansen C. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J. Clin. Endocrinol. Metab. 1999, 84:2363-2368.
58. Braga de Castro Machado A., Hannon R., Eastell R. Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res. 1999, 14:602-608.
59. Garnero P., Darte C., Delmas P.D. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999, 24:603-609.
60. Greenspan S.L., Rosen H.N., Parker R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J. Clin. Endocrinol. Metab. 2000, 85:3537-3540.
61. Ravn P., Thompson D.E., Ross P.D., Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003, 33:150-158.
62. Mortensen L., Charles P., Bekker P.J., Digennaro J., Johnston C.C. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metab. 1998, 83:396-402.
63. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut C.H., Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., Miller P.D. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
64. Raisz L., Smith J.A., Trahiotis M., Fall P., Shoukri K., Digennaro J., Sacco-Gibson N. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos. Int. 2000, 11:615-620.
65. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., Li Z., Balske A., Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. 2002, 71:103-111.
66. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 2003, 18:1051-1056.
67. Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996, 19:527-533.
68. Thiebaud D., Burckhardt P., Kriegbaum H., Huss H., Mulder H., Juttmann J.R., Schoter K.H. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. 1997, 103:298-307.
69. Ravn P., Christensen J.O., Baumann M., Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 1998, 22:559-564.
70. Cooper C., Emkey R.D., McDonald R.H., Hawker G., Bianchi G., Wilson K., Schimmer R.C. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2003, 88:4609-4615.
71. Christiansen C., Tanko L.B., Warming L., Moelgaard A., Christgau S., Qvist P., Baumann M., Wieczorek L., Hoyle N. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos. Int. 2003, 14:609-613.
72. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner. Res. 1995, 10:641-649.
73. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., Widmer A., Devogelaer J.P., Kaufman J.M., Jaeger P., Body J.J., Brandi M.L., Broell J., Di Micco R., Genazzani A.R., Felsenberg D., Happ J., Hooper M.J., Ittner J., Leb G., Mallmin H., Murray T., Ortolani S., Rubinacci A., Saaf M., Sansioe G., Verbruggen L., Meunier P.J. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002, 346:653-661.
74. Evio S., Tiitinen A., Laitinen K., Ylikorkala O., Valimaki M.J. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J. Clin. Endocrinol. Metab. 2004, 89:626-631.
75. Johnell O., Scheele W.H., Lu Y., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 2002, 87:985-992.
76. Sambrook P.N., Geusens P., Ribot C., Solimano J.A., Ferrer-Barriendos J., Gaines K., Verbruggen N., Melton M.E. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J. Intern. Med. 2004, 255:503-511.
77. Pedrazzoni M., Alfano F.S., Gatti C., Fantuzzi M., Girasole G., Campanini C., Basini G., Passeri M. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif. Tissue Int. 1995, 57:25-29.
78. Seibel M.J., Woitge H.W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., Armbruster F.P., Ziegler R. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J. Clin. Endocrinol. Metab. 1996, 81:3289-3294.
79. Apone S., Lee M.Y., Eyre D.R. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997, 21:129-136.
80. Randall A.G., Kent G.N., Garcia-Webb P., Bhagat C.I., Pearce D.J., Gutteridge D.H., Prince R.L., Stewart G., Stuckey B., Will R.K., Retallack R.W., Price R.L., Ward L. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J. Bone Miner. Res. 1996, 11:1176-1184.
81. Meunier P.J., Confavreux E., Tupinon I., Hardouin C., Delmas P.D., Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J. Clin. Endocrinol. Metab. 1997, 82:2784-2791.
82. Rossini M., Gatti D., Zamberlan N., Braga V., Dorizzi R., Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J. Bone Miner. Res. 1994, 9:1833-1837.
83. Greenspan S.L., Emkey R.D., Bone H.G., Weiss S.R., Bell N.H., Downs R.W., McKeever C., Miller S.S., Davidson M., Bolognese M.A., Mulloy A.L., Heyden N., Wu M., Kaur A., Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2002, 137:875-883.
84. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., Rodriguez-Portales J.A., Downs R.W., Gupta J., Santora A.C., Liberman U.A. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004, 18:1189-1199.
85. Harris S.T., Eriksen E.F., Davidson M., Ettinger M.P., Moffett A.H., Baylink D.J., Crusan C.E., Chines A.A. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 2001, 86:1890-1897.
86. Overgaard K., Christiansen C. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif. Tissue Int. 1996, 59:12-16.
87. Kraenzlin M.E., Seibel M.J., Trechsel U., Boerlin V., Azria M., Kraenzlin C.A., Haas H.G. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif. Tissue Int. 1996, 58:216-220.
88. Thamsborg G., Jensen J.E., Kollerup G., Hauge E.M., Melsen F., Sorensen O.H. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996, 18:207-212.
89. Ongphiphadhanakul B., Piaseu N., Chailurkit L., Rajatanavin R. Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover. Calcif. Tissue Int. 1998, 62:379-382.
90. Downs R.W., Bell N.H., Ettinger M.P., Walsh B.W., Favus M.J., Mako B., Wang L., Smith M.E., Gormley G.J., Melton M.E. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J. Clin. Endocrinol. Metab. 2000, 85:1783-1788.
91. Trovas G.P., Lyritis G.P., Galanos A., Raptou P., Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J. Bone Miner. Res. 2002, 17:521-527.
92. Buclin T., Cosma Rochat M., Burckhardt P., Azria M., Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J. Bone Miner. Res. 2002, 17:1478-1485.
93. Adami S., Passeri M., Ortolani S., Broggini M., Carratelli L., Caruso I., Gandolini G., Gnessi L., Laurenzi M., Lombardi A., Norbiato G., Pryor-Tillstson S., Reda C., Romanini L., Subriji D., Wei L., Yates A.J. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995, 17:383-390.
94. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
95. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997, 234:137-142.
96. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 2001, 16:348-360.
97. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., Holmes G.B., Dunstan C.R., DePaoli A.M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 2004, 19:1059-1066.
98. Seibel M.J. Biochemical markers of bone remodeling. Endocrinol. Metab. Clin. North Am. 2003, 32:83-113.
99. Seibel M.J. Biochemical markers of bone remodeling. Endocrinol. Metab. Clin. North Am. 2003, 32:vi-vii.
100. Filipponi P., Pedetti M., Fedeli L., Cini L., Palumbo R., Boldrini S., Massoni C., Cristallini S. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res. 1995, 10:697-703.
101. Dresner-Pollak R., Mayer M., Hochner-Celiniker D. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women. Calcif. Tissue Int. 2000, 66:104-107.
102. Bjarnason N.H., Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000, 26:561-569.
103. Komulainen M., Kroger H., Tuppurainen M.T., Heikkinen A.M., Honkanen R., Saarikoski S. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos. Int. 2000, 11:211-218.
104. Fall P.M., Kennedy D., Smith J.A., Seibel M.J., Raisz L.G. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos. Int. 2000, 11:481-485.
105. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999, 24:237-244.
106. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., Souberbielle J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int. 2000, 11:295-303.
107. Bone H.G., Greenspan S.L., McKeever C., Bell N., Davidson M., Downs R.W., Emkey R., Meunier P.J., Miller S.S., Mulloy A.L., Recker R.R., Weiss S.R., Heyden N., Musliner T., Suryawanshi S., Yates A.J., Lombardi A. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J. Clin. Endocrinol. Metab. 2000, 85:720-726.
108. Watts N.B., Jenkins D.K., Visor J.M., Casal D.C., Geusens P. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate. Osteoporos. Int. 2001, 12:279-288.
109. Storm T., Thamsborg G., Steiniche T., Genant H.K., Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 1990, 322:1265-1271.
110. Overgaard K., Hansen M.A., Jensen S.B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992, 305:556-561.
111. Lufkin E.G., Wahner H.W., O'Fallon W.M., Hodgson S.F., Kotowicz M.A., Lane A.W., Judd H.L., Caplan R.H., Riggs B.L. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. 1992, 117:1-9.
112. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 1995, 333:1437-1443.
113. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates A.J., LaCroix A.Z. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
114. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 2002, 17:1-10.
115. Li Z., Meredith M.P. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics. J. Biopharm. Stat. 2003, 13:777-792.
116. Riggs B.L., Melton L.J., O'Fallon W.M. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996, 18:197S-201S.
117. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 2001, 12:922-930.
118. Sarkar S., Reginster J.Y., Crans G.G., Diez-Perez A., Pinette K.V., Delmas P.D. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J. Bone Miner. Res. 2004, 19:394-401.
119. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., Thompson D.E., Ewing S.K., Delmas P.D. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 2004, 19:1250-1258.
120. McCombs J.S., Thiebaud P., McLaughlin-Miley C., Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48:271-287.
121. Marwick C. Hormone combination treats women's bone loss. JAMA 1994, 272:1487.
122. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994, 20:91-99.
123. Faulkner D.L., Young C., Hutchins D., McCollam J.S. Patient noncompliance with hormone replacement therapy: a nation-wide estimate using a large prescription claims database. Menopause 1998, 5:226-229.
124. Kotzan J.A., Martin B.C., Wade W.E. Persistence with estrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 1999, 19:363-369.
125. Kayser J., Ettinger B., Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001, 8:328-332.
126. Bjorn I., Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999, 32:77-86.
127. Segal E., Tamir A., Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr. Med. Assoc. J. 2003, 5:859-862.
128. Chapurlat R.D., Cummings S.R. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?. Osteoporos. Int. 2002, 13:738-744.
129. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2004, 89:1117-1123.
130. Delmas P.D., Vrijens B., Roux C., Le-Moigne-Amrani A., Eastell R., Grauer A., Watts N.B., Pols H.A., Ringe J.D., Cahall D. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: The IMPACT Study. J. Bone Miner. Res. 2003, 18:S374.
131. Di Munno O., Mazzantini M., Braga V., Adami S. The DOMINO Project: To improve the compliance of osteoporotic patients with periodic feedback of urinary CTX values. J. Bone Miner. Res. 2002, 17:S374.
132. Nguyen T.V., Eisman J.A. Assessment of significant change in BMD: a new approach. J. Bone Miner. Res. 2000, 15:369-372.
133. Congdon P. Bayesian statistical modelling 2002, 11-61. Wiley, New York.
134. Berry D.A. Statistics: A perspective 1996, 336-368. Duxbury Press, Belmont.
135. Spiegelhalter D.J., Freedman L.S., Parmar M.K. Bayesian approaches to randomised trials. J. Royal Statist. Soc. Series A 1994, 157:357-416.
136. Howson C., Urbach P. Scientific reasoning: The Bayesian Approach 1993, 357-416. Open Court. La salle, La salle.
137. Seibel M.J., Lang M., Geilenkeuser W.J. Interlaboratory variation of biochemical markers of bone turnover. Clin. Chem. 2001, 47:1443-1450.